Stockscreener 앱 받기
1.80
2.70%
-0.05
시간 외 거래:
1.80
전일 마감가:
$1.85
열려 있는:
$1.805
하루 거래량:
481.84K
Relative Volume:
1.65
시가총액:
$46.88M
수익:
-
순이익/손실:
$-49.81M
주가수익비율:
-0.8349
EPS:
-2.156
순현금흐름:
$-42.93M
1주 성능:
-20.70%
1개월 성능:
-42.12%
6개월 성능:
-82.78%
1년 성능:
-87.22%
1일 변동 폭
$1.60
$1.8203
1주일 범위
$1.60
$2.25
52주 변동 폭
$1.60
$17.55
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
ANRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
1.80 | 46.88M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Alto Neuroscience advances trial for depression treatment - MSN
ANRO stock touches 52-week low at $2.97 amid market challenges - Investing.com Canada
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker - Marketscreener.com
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care - StockTitan
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Stifel maintains Buy on Alto Neuroscience stock, $10 target - MSN
Alto Neuroscience advances trial for depression treatment By Investing.com - Investing.com Australia
Stifel maintains Buy on Alto Neuroscience stock, $10 target By Investing.com - Investing.com Nigeria
Alto Neuroscience : Corporate Presentation -February 12, 2025 at 08:29 am EST - Marketscreener.com
Alto Neuroscience announces interim analysis from ALTO-300 trial - TipRanks
Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial - Marketscreener.com
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - The Bakersfield Californian
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Louisiana First News
Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat
Alto Neuroscience announces $75 million ATM offering - MSN
Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com
Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.70%
자본화:
|
볼륨(24시간):